

9-7-07

IPW

1633

PTO/SB/21 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission	1	Attorney Docket Number	39387-012 US NAT'L (INTM/018)
--	---	------------------------	-------------------------------

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1) Form PTO/SB/08a; 2) 10 cited references; 3) Return Receipt Postcard.
---	--	--

Remarks


The Director is hereby authorized to charge payment of any fees required in connection with filing of these papers to Deposit Account No. 06-1075, Order No. 104825-0018. A duplicate copy of this letter is transmitted herewith.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Ropes & Gray LLP		
Signature			
Printed name	Karen Mangasarian		
Date	September 5, 2007	Reg. No.	43,772

CERTIFICATE OF EXPRESS MAIL (EXPRESS MAIL LABEL NO. EM016026181US)

I hereby certify that this correspondence is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450:

Signature			
Typed or printed name	ROSE MARIE DHANRAJ	Date	September 5, 2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc.
www.FormsWorkflow.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Quinn T. Tang et al.
Application No. : 10/554,442 Confirmation No.: 1361
Filed : December 12, 2006
For : RNAi AGENTS FOR ANTI-SARS
CORONAVIRUS THERAPY
Examiner : Not Yet Assigned
Group Art Unit : 1633

New York, New York
September 5, 2007

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants hereby make of record the documents listed in the accompanying PTO/SB/08A form. Copies of the documents listed therein are submitted herewith.

Applicants request that the cited document be (1) fully considered by the Examiner during the course of examination of this application, and (2) printed on any patent issuing from this application. Additionally, applicants request that a copy of Form PTO/SB/08A, as considered and initialed by the Examiner, be returned with the next communication.

This Statement is submitted before the mailing of the first Office Action on the merits. In accordance with 37 C.F.R. § 1.97 (b)(3), no fee is due in connection with this Statement. However, if for any reason a fee is due, the Director is hereby authorized to charge payment of the fee to Deposit Account No. 06-1075, Order No. 104825-0018. A duplicate copy of this Statement is enclosed.

Respectfully submitted,



Jane T. Gunnison (Reg. No. 38,479)
Karen Mangasarian (Reg. No. 43,772)
Attorneys for Applicants
c/o ROPES & GRAY LLP
1211 Avenue of the Americas
New York, New York 10036
Tel.: (212) 596-9000
Fax: (212) 596-9090



PTO/SB/08a (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	39387-012 US NAT'L (INTM/018)
-------	---	----	---	------------------------	-------------------------------

Complete if Known

Application Number	10/554,442
Filing Date	December 12, 2006
First Named Inventor	Quinn T. Tang
Art Unit	1633
Examiner Name	Not Yet Assigned

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		WO 02/078631 A2	10-10-2002	Virxsys	
		WO 04/092360 A2	10-28-2004	Chiron Corporation	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		COBURN, Glen A., et al., "siRNAs: a new wave of RNA-based therapeutics," <i>Journal of Antimicrobial Chemotherapy</i> , 51:753-756, 2003.	
		CULLEN, Bryan R., "RNA interference: antiviral defense and genetic tool," <i>Nature Immunology</i> , 3(7):597-599, 2002.	
		GE, Qing, et al., "RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription," <i>Proc. Nat'l Acad. Of Sciences USA</i> , 100(5):2718-2723, 2003.	
		GITLIN, Leonid, et al., "Short interfering RNA confers intracellular antiviral immunity in human cells," <i>Nature</i> , 418:430-434, 2002.	
		KSIAZEK, Thomas G., et al., "A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome," <i>The New England Journal of Medicine</i> , 348(20):1953-1966, 2003.	
		PEIRIS, J.S.M., et al., "Coronavirus as a possible cause of severe acute respiratory syndrome," <i>The Lancet</i> , 361:1319-1325, 2003.	
		ZHANG, R, et al., "Inhibiting severe acute respiratory syndrome-associated coronavirus by small interfering RNA," <i>Chinese Medical Journal</i> , 116(8):1262-1264, 2003.	
		ZHANG, Y., et al., "Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference," <i>FEBS Letters</i> , 560:141-146, 2004.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

EXPRESS MAIL LABEL NO. EM016026181US